Bayraktar, E. Et Al. 2023. In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders. British Journal of Pharmacology , vol.180, no.8 , 1038-1055.

Bayraktar, E., Liu, Y., Sonnenberg, L., Hedrich, U. B. S., Sara, Y., Eltokhi, A., ... Lyu, H.(2023). In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders. British Journal of Pharmacology , vol.180, no.8, 1038-1055.

Bayraktar, Erva Et Al. "In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders," British Journal of Pharmacology , vol.180, no.8, 1038-1055, 2023

Bayraktar, Erva Et Al. "In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders." British Journal of Pharmacology , vol.180, no.8, pp.1038-1055, 2023

Bayraktar, E. Et Al. (2023) . "In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders." British Journal of Pharmacology , vol.180, no.8, pp.1038-1055.

@article{article, author={Erva Bayraktar Et Al. }, title={In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders}, journal={British Journal of Pharmacology}, year=2023, pages={1038-1055} }